Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Market Report and Forecast 2024-2032

Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Market Outlook

The Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment market is expected to grow at a CAGR of 7.9% during the forecast period of 2024-2032, driven by the growing awareness of rare diseases.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Atypical Teratoid Rhabdoid Treatment Market: Insights

Atypical Teratoid Rhabdoid (ATRT) is a primary tumour in the central nervous system (CNS). It begins in the brain or spinal cord. Primary CNS tumours are graded based on the location of the tumour, the type of tumour, the extent of tumour spread, genetic findings, the patient's age, and the amount of tumour that remains after surgery, if surgery is possible.

ATRTs are all considered Grade IV tumours. This indicates that they are malignant (cancerous) and rapidly growing. Cancer is a genetic disease, which means that it is caused by changes in genes that control how our cells function. In many types of cancer, genes can be mutated (changed), causing cancer cells to grow and spread. 

Majority of ATRTs are caused by mutations in the SMARCB1 gene (also called INI1). This gene normally sends signals to proteins that inhibit tumour growth. SMARCB1 does not function properly in ATRTs, and tumour growth is uncontrolled. SM ARCB1 is sometimes found in a person's DNA, indicating that they are born with it. ATRTs can grow very quickly. They frequently spread to other areas of the CNS via cerebrospinal fluid (CSF).

The symptoms of an ATRT vary, depending on the location of the tumour and the age of the person. Some of the most common symptoms are as follows:

• Headaches

• Vomiting

• Variations in Activity Levels

• Loss of Equilibrium

• Increased Size of the Head

Symptoms usually worsen quickly as the ATRTs grow quickly.

According to the market research report, the atypical teratoid rhabdoid treatment market can be categorised into the following segments:

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Breakup by Treatment Method

• Surgery

• Chemotherapy

• Radiation

• Targeted Immunotherapy

Market Breakup by Route of Administration

• Oral

• Parenteral

• Intravitreal

• Subretinal

• Topical

• Molecule Type

Market Breakup by Treatment Channel

• Public

• Private

Market Breakup by Region

• North America
  • United States of America
  • Canada
• Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Others
• Asia Pacific
  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Others
• Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Atypical Teratoid Rhabdoid Epidemiology

ATRTs can occur likewise in children and adults but they are extremely rare in both the age groups. This tumour affects an estimated 596 people in the United States. ATRTs are more prevalent in men than in women.

Global Atypical Teratoid Rhabdoid Therapeutic Landscape

The first line of treatment for an ATRT is surgery. The surgery aims at obtaining tissue to determine the tumour and its type and to remove the tumour to the largest extent without exacerbating the patient's symptoms.

Following surgery, people with ATRTs typically receive additional treatments, such as radiation, chemotherapy, or clinical trials. Clinical trials involving new chemotherapy, targeted therapy, or immunotherapy drugs may also be available as a treatment option. The patient's healthcare team decides on treatments based on the patient's age, remaining tumour after surgery, tumour type, and tumour location.

Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Market Drivers and Constraints

The population growing awareness of rare and genetic disorders is expected to drive the demand for the market. The number of leading pharmaceutical companies, with products in clinical trials for the treatment of atypical teratoid rhabdoid, will drive the market growth. 

The growth of the market can be hampered by the small patient population available for clinical trials.

Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment Competitive Landscape

The report gives an in-depth analysis of the key players involved in the Global Atypical Teratoid Rhabdoid Tumours (ATRT) Treatment market, sponsors manufacturing the therapies, and putting them through trials to get FDA approvals. The companies included in the market are as follows:  

• Takeda Pharmaceutical Company

• Vyriad Inc

• Novartis AG

• Istari Oncology Inc.

• Secura Bio, Inc.

• Pfizer, Inc.

• Ipsen Pharma

• Exelixis, Inc.

Key Highlights of the Report